Literature DB >> 17508724

Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease.

Jianhui Zhu1, Betsy T Kren, Chang Won Park, Rasim Bilgim, Phillip Y-P Wong, Clifford J Steer.   

Abstract

Sickle cell disease (SCD) results predominately from a single monogenic mutation that affects thousands of individuals worldwide. Gene therapy approaches have focused on using viral vectors to transfer wild-type beta- or gamma-globin transgenes into hematopoietic stem cells for long-term expression of the recombinant globins. In this study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transposon (Tn) to insert a wild-type beta-globin expression cassette into the human genome for sustained expression of beta-globin. We initially constructed a beta-globin expression vector composed of the hybrid cytomegalovirus (CMV) enhancer chicken beta-actin promoter (CAGGS) and full-length beta-globin cDNA, as well as truncated forms lacking either the 3' or 3' and 5' untranslated regions (UTRs), to optimize expression of beta-globin. Beta-globin with its 5' UTR was efficiently expressed from its cDNA in K-562 cells induced with hemin. However, expression was constitutive and not erythroid-specific. We then constructed cis SB-Tn-beta-globin plasmids using a minimal beta-globin gene driven by hybrid promoter IHK (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, ankyrin-1 promoter), IHbetap (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, beta-globin promoter), or HS3betap (HS3 core element from human betaLCR, beta-globin promoter) to establish erythroid-specific expression of beta-globin. Stable genomic insertion of the minimal gene and expression of the beta-globin transgene for >5 months at a level comparable to that of the endogenous gamma-globin gene were achieved using a SB-Tn beta-globin cis construct. Interestingly, erythroid-specific expression of beta-globin driven by IHK was regulated primarily at the translational level, in contrast to post-transcriptional regulation in non-erythroid cells. The SB-Tn system is a promising nonviral vector for efficient genomic insertion conferring stable, persistent erythroid-specific expression of beta-globin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508724      PMCID: PMC3893920          DOI: 10.1021/bi6024484

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

1.  A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice.

Authors:  D E Sabatino; C Wong; A P Cline; L Pyle; L J Garrett; P G Gallagher; D M Bodine
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

2.  Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse.

Authors:  Lara S Collier; Corey M Carlson; Shruthi Ravimohan; Adam J Dupuy; David A Largaespada
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

3.  A multipotential leukemia cell line (K-562) of human origin.

Authors:  B B Lozzio; C B Lozzio; E G Bamberger; A S Feliu
Journal:  Proc Soc Exp Biol Med       Date:  1981-04

4.  The human ankyrin-1 gene is selectively transcribed in erythroid cell lines despite the presence of a housekeeping-like promoter.

Authors:  P G Gallagher; M Romana; W T Tse; S E Lux; B G Forget
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

5.  Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression.

Authors:  K Qing; J Hansen; K A Weigel-Kelley; M Tan; S Zhou; A Srivastava
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter.

Authors:  D E Sabatino; N E Seidel; G J Aviles-Mendoza; A P Cline; S M Anderson; P G Gallagher; D M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

7.  Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates.

Authors:  Z Izsvák; Z Ivics; R H Plasterk
Journal:  J Mol Biol       Date:  2000-09-08       Impact factor: 5.469

8.  Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release.

Authors:  B Wagenknecht; M Hermisson; P Groscurth; P Liston; P H Krammer; M Weller
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

Review 9.  Toward gene therapy for disorders of globin synthesis.

Authors:  J Tisdale; M Sadelain
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

10.  High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors.

Authors:  F Moreau-Gaudry; P Xia; G Jiang; N P Perelman; G Bauer; J Ellis; K H Surinya; F Mavilio; C K Shen; P Malik
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

View more
  12 in total

1.  Long-term and efficient expression of human β-globin gene in a hematopoietic cell line using a new site-specific integrating non-viral system.

Authors:  K Dormiani; H Mir Mohammad Sadeghi; H Sadeghi-Aliabadi; K Ghaedi; M Forouzanfar; H Baharvand; M H Nasr-Esfahani
Journal:  Gene Ther       Date:  2015-04-01       Impact factor: 5.250

Review 2.  Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.

Authors:  Zsuzsanna Izsvák; Perry B Hackett; Laurence J N Cooper; Zoltán Ivics
Journal:  Bioessays       Date:  2010-09       Impact factor: 4.345

3.  β-globin matrix attachment region improves stable genomic expression of the Sleeping Beauty transposon.

Authors:  Lucas Sjeklocha; Yixin Chen; Meghan C Daly; Clifford J Steer; Betsy T Kren
Journal:  J Cell Biochem       Date:  2011-09       Impact factor: 4.429

4.  Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

Authors:  Betsy T Kren; Gretchen M Unger; Lucas Sjeklocha; Alycia A Trossen; Vicci Korman; Brenda M Diethelm-Okita; Mark T Reding; Clifford J Steer
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

5.  Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon.

Authors:  Xia Wang; Debi P Sarkar; Prashant Mani; Clifford J Steer; Yong Chen; Chandan Guha; Voshavar Chandrasekhar; Arabinda Chaudhuri; Namita Roy-Chowdhury; Betsy T Kren; Jayanta Roy-Chowdhury
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

6.  High-level genomic integration, epigenetic changes, and expression of sleeping beauty transgene.

Authors:  Jianhui Zhu; Chang Won Park; Lucas Sjeklocha; Betsy T Kren; Clifford J Steer
Journal:  Biochemistry       Date:  2010-02-23       Impact factor: 3.162

7.  The expanding universe of transposon technologies for gene and cell engineering.

Authors:  Zoltán Ivics; Zsuzsanna Izsvák
Journal:  Mob DNA       Date:  2010-12-07

8.  Erythroid-specific expression of β-globin from Sleeping Beauty-transduced human hematopoietic progenitor cells.

Authors:  Lucas M Sjeklocha; Chang-Won Park; Phillip Y-P Wong; Mark J Roney; John D Belcher; Dan S Kaufman; Gregory M Vercellotti; Robert P Hebbel; Clifford J Steer
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

9.  Restoration of dystrophin expression using the Sleeping Beauty transposon.

Authors:  Sofia Muses; Jennifer E Morgan; Dominic J Wells
Journal:  PLoS Curr       Date:  2011-12-22

10.  A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.

Authors:  Guipeng Ding; Ximin Chen; Jin Zhu; Nicholas S Duesbery; Xunjia Cheng; Brian Cao
Journal:  Clin Dev Immunol       Date:  2013-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.